Cargando…

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yee, Andrew J, Raje, Noopur S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437759/ https://www.ncbi.nlm.nih.gov/pubmed/22977302 http://dx.doi.org/10.2147/CIA.S14566

Ejemplares similares

The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
por: Castellano, Daniel, et al.
Publicado: (2011)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman, Ursa, et al.
Publicado: (2013)

Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler, Robert A, et al.
Publicado: (2011)

Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
por: Dhabhar, Boman
Publicado: (2022)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

RANKL/RANK: from bone loss to the prevention of breast cancer
por: Sigl, Verena, et al.
Publicado: (2016)

Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
por: Lipton, Allan, et al.
Publicado: (2012)

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

RANK-Ligand inhibitor associated osteonecrosis of the jaw
por: Rashad, Ashkan, et al.
Publicado: (2013)

Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma
por: Buckle, Clive Henry, et al.
Publicado: (2012)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Denosumab might prevent periprosthetic bone loss after total hip and knee arthroplasties: a review
por: Xu, Jianda, et al.
Publicado: (2021)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015)

Giant-cell tumor of bone: treatment options and role of denosumab
por: Singh, Arun S, et al.
Publicado: (2015)

RANK and RANK ligand expression in primary human osteosarcoma
por: Branstetter, Daniel, et al.
Publicado: (2015)

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021)

Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals
por: Lin, Sheng-Chieh, et al.
Publicado: (2023)

Radiological findings of denosumab treatment for giant cell tumours of bone
por: van Langevelde, Kirsten, et al.
Publicado: (2020)

The Effect of Denosumab on Bone Mass in Super Elderly Patients
por: Jeong, Chaiho, et al.
Publicado: (2020)

The role of RANK ligand/OPG system in bone erosions in rheumatoid arthritis
por: Geusens, Piet
Publicado: (2012)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
por: Borkowska, Aneta Maria, et al.
Publicado: (2022)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
por: Gaston, Czar Louie, et al.
Publicado: (2016)

What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary
por: Moretti, Antimo
Publicado: (2021)

Fusing similarity rankings in ligand-based virtual screening
por: Willett, Peter
Publicado: (2013)

Lifestyle considerations in multiple myeloma
por: Shapiro, Yael N., et al.
Publicado: (2021)

Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review
por: Alhumaid, Ibrahim, et al.
Publicado: (2019)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bpmntrjbsad5ci70fdrq54nv3k